SCREENING CRYSTALLISATION CONDITIONS OF ORGANIC COMPOUNDS

Abstract: A method for identifying crystallisation conditions for at least one analyte, comprising the provision of a set of compositions each said composition comprising at least one analyte, and inducing or allowing each composition to adopt at least a first condition possibly influencing crystallisation and detecting any crystallisation in at least one composition.

Description: Title: Screening crystallisation conditions of organic compounds The present invention relates to methods for crystal forms (polymorphs) for analytes using e.g. a method and an apparatus for screening the phase behaviour, more in particular crystallisation behaviour in liquid, gel or solid phase of such analytes, such as organic molecules, for instance pharmaceutically interesting compounds and complexes, oligomers, salts, esters and solvates thereof, organometallic molecules such as catalysts for homogenous catalysis etc. The present invention also relates to the parallel detection of phase transitions, more specific crystallisation, of these analytes. The present invention also provides methods for producing crystals of analytes on any desired scale using the conditions identified according to the invention. Further uses of the crystals and compositions comprising such crystals are also provided. Crystals of analytes according to the invention can also be used to collect information on the structure of analytes, more in particular in relation to the existence of crystal polymorphism. The invention provides for a method for the rapid determination of crystal polymorphism. Crystallisation is in general considered as the separation or precipitation out of a liquid environment. The basic approach to crystallisation is usually fairly simple. The molecule to be crystallised is dissolved or suspended and subsequently subjected to conditions that affect the solubility of the molecule in solution. This can be achieved by removal of the solvent or by the addition of other compounds that reduce the solubility, optionally in combination with variation of other factors such temperature, pressure or gravitational forces. When the conditions are right, small nuclei will form from which crystals will grow. However, the relations between the conditions and the crystallisation are generally not well understood. The optimisation of the crystallisation conditions is largely based on trial and error. To determine the optimal crystallisation conditions can therefor be a laborious and time-consuming process. Many molecules can crystallise in different crystal forms, a phenomenon known as polymorphism. The appearance of these different crystalline forms is strongly dependent on the physical and chemical environment in which the crystal nucleates, grows or is exposed to after growth. Different crystalline forms result from different conditions under which the crystallisation is carried out. However, there is no significant theoretical framework that allows to predict reliably whether specific polymorphic forms of a molecule exist or can be expected and if so how these can be produced. The identification of polymorphic behaviour of molecules and determining the conditions under which the different polymorphic forms can be obtained therefor has to be done experimentally, a time-consuming and labour intensive process. Once the material is in a crystalline form, valuable information can be obtained pertaining to the three-dimensional structure of the molecule. Furthermore valuable information can be obtained from different crystalline forms of molecules. For instance, different polymorphic forms may express different dissolution behaviour, or even express different properties in terms of biological activity. Many pharmaceutically and/or industrially important molecules such as drug molecules or catalysts for homogenous catalysis are solids at room temperature. More often than not these molecules crystallise in distinct structural forms, thus exhibiting polymorphic behaviour. It is therefor of interest to obtain information on the crystallisation behaviour of such compounds. The crystallisation behaviour of a compound is determined mostly by its stereochemistry. This obviously comprises its covalent bonding pattern, but also its ionic structure as determined by the presence of any available counter-ions in the crystal lattice. Next to this chemical makeup, other external parameters also affect the crystallisation of organic compounds such as concentration of the compound in the mother liquor, hydrophobicity/polarity of the solvents, temperature, speed of crystal-formation (nucleation), pressure and many others. Due to this large number of parameters that affect crystallisation, determining the optimal combination of parameters results in an overwhelming amount of possible combinations. Conventional linear optimisation (testing one condition after the other) based on trial and error is hence a long and cumbersome method, if at all feasible. It is therefor an object of the present invention to provide methods in which testing of many combinations is possible and can be done efficiently and rapidly and preferably in parallel, i.e. testing various combinations of parameters at the same time. Conventional linear optimisation as described above is also common practice in the search for polymorphs of small organic compounds. By serially screening many different conditions separately and evaluating the results, each in standard laboratory glassware the desired information can be collected, albeit at a very slow pace. Harvesting of the crystalline material (for instance in the form of powders) before characterisation is usually done manually, one at a time. The present invention intends to provide for improvements in determining crystallisation conditions in general and in particular the determination of polymorphic behaviour. The invention further intends to overcome the above- mentioned disadvantages of the conventional techniques. The present inventors have found a method for the screening of a large number of crystallisation conditions. Further they have devised a way for the screening of a large number of crystallisation conditions in parallel and for the identification of crystal polymorphs. A method and an apparatus is disclosed for generating and analysing, preferably in parallel, multiple crystal forms (polymorphs) of chemical substance or mixtures of substances (the analyte) from which preferably at least one crystal form is known. To this end an array of solutions, or at least one solution, is provided, for instance in a range of solvents or solvent mixtures, or at least one solvent. The analyte may be provided in a specially designed substrate, but a conventional substrate such as a micro titerplate may suffice provided that some conditions are fulfilled which are exemplified in the various embodiments. Conditions under which the analytes are kept in the substrate are changed, for instance by altering or modifying physical or chemical conditions such as lowering the temperature or allowing solvent to evaporate. The crystallisation of the analytes may be induced by a change in these physical or chemical conditions. The insoluble material is analysed, for instance by X-ray diffraction techniques and preferably in transmission geometry. The analysis of the insoluble material can be performed in situ on the substrate or by transferring the insoluble fractions of the analytes to a carrier. The X-ray diffraction patterns are, preferably automatically, corrected and compared. The patterns of different analytes are compared, thereby allowing the identification of different polymorphs and the conditions under which these polymorphs form or are converted from one polymorphic form into another. The invention in one aspect relates to a method for detecting polymorphism of at least one analyte, comprising the provision of a set of compositions comprising at least one analyte, and inducing or allowing each composition to adopt at least a first condition possibly influencing crystallisation and detecting any crystallisation in at least one composition. Analyte within the terms of the present invention is a compound of which the crystallisation behaviour is to be determined. An analyte in terms of the invention is a chemical substance or a mixture of different substances of which substance at least one crystal form is known or of which it is expected that at least one crystal form exists. An analyte in terms of the invention is preferably an organic or organometallic molecule or compound, such as a pharmaceutically active molecules or catalyst-ligand complex or a dimer, salt, ester or solvate thereof. In another aspect an analyte in terms of the present invention can also be a biomolecule i.e. nucleic acids, DNA's, RNA's, PNA's, polypeptides, peptides, glycoproteins and other proteinaceous substances, lipoproteins protein-nucleic acid complexes, carbohydrates, biomimetics, etc. One preferred way of working the method of the present invention comprises providing a substrate comprising an array of optionally sealable containers, which containers are optionally provided with means to induce crystallisation, such as substances that alter or influence crystallisation behaviour such as nucleation agents, depositing separate volumes of analytes in the form of solids, slurries, emulsions or solutions and whereby the composition of each container differs in at least one aspect from the composition of at least one other container, optionally sealing off the containers from the atmosphere, optionally providing the containers with an atmosphere that influences the crystallisation behaviour, allowing crystalline material to form, manipulating the obtained crystalline material diffraction, for instance by removal of the solvents or providing the crystalline material on a carrier material to allow for analysis of the crystalline structure, preferably by X-ray diffraction techniques, preferably automatically determining the X-ray diffraction patterns of optionally selected analytes or compositions, optionally comparing the diffraction patterns of the analytes or compositions, optionally correcting the diffraction patterns for background fluctuations, optionally identifying polymorphs of the analyte and optionally relating the occurrence and the crystal form of the polymorphs to the composition and condition to which the analyte has been subjected. The substrate is preferably chemically inert to the substances and solvents employed and is preferably transparent to the detection technique used, e.g. X-ray transparent in case of X-ray diffraction technique. If the substrate is not transparent to X-rays, the array of samples may be measured in reflection X-ray diffraction geometry, but preferably are measured in transmission X-ray diffraction geometry after transferring the samples sequentially, but preferably in parallel, to an X-ray transparent carrier. The substrate is preferably also transparent to visual light (ca 200 nm to 1000 nm) to allow visual or optical inspection. The substrate is preferably also capable of transferring heat, thereby allowing for temperature variations. Examples of arrays are 8 by 12 up to 32 by 48, with orthogonal centre to centre distance varying from 2 to 10 mm between the containers or wells of the substrate. The determination of the polymorphic forms of the analyte is preferably achieved by electron diffraction or by X-ray diffraction technology. Different polymorphs of an analyte produce different diffraction patterns. By determining the diffraction patterns, preferably in transmission geometry, from the crystallised analytes and comparing these diffraction patterns, information is obtained relating the different crystallisation conditions to different crystalline forms of the analyte. The determination of the X-ray diffraction characteristics of the crystallised analytes can conveniently be carried out in the provided array in which the crystallisation method has been carried out (in-situ). In transmission diffraction geometry, the preferred implementation, this requires that the array itself is transparent to X-ray diffraction or that the background diffraction pattern from the array is determined and the obtained X-ray diffraction data from the crystal in the array are corrected for this background pattern. It is likewise possible to remove all crystallites from the substrate medium onto a carrier substrate, for instance by simultaneous filtration of all crystalline material, slurries etc. that are present in the wells of the medium. This allows for an analysis of crystalline material with reduced background signals from solvents etc. The advantage of using a transmission geometry over more conventional reflection geometry of the diffraction experiments, is that substantially more signal is measured per mass unit of analyte. It is thus possible to use milligram, preferably nanogram or picogram amounts of material and still achieve an improved throughput. The determination of the existence of different polymorphs of an analyte can be used to determine and/or optimising the conditions for the conversion of one crystal form of the analyte into another form of the analyte. An advantageous aspect of the present invention pertains to a method for optimising the conditions of the transformation of one polymorphic form of an analyte into another polymorphic form by subjecting the one polymorphic form of the analyte to the method for detecting polymorphism of the present invention. According to the invention, preferably a plurality of different conditions is provided, each differing in at least one parameter which influences the crystallisation behaviour of the analyte to be crystallised. In an embodiment of the invention, the different conditions can be chemical or physical. A chemical condition in general comprises different (concentrations of) solvents, buffers, precipitants, salts etc. A physical condition is seen in terms of temperature, pressure etc. Although the art generally teaches that large quantities of material are required for successful crystallisation we have shown that sub-microgram quantities can be used for small molecules (molecular weight in the order of less than 500 grams per mole) and even down to 1 nanogram quantities for proteins (molecular weight in the order of more than 5000 grams per mole). Because of the small volumes that can be used in the methods according to the invention, availabihty of analytes is less of a problem and rapid testing of numerous conditions and easy adjustment of relevant conditions is easily obtained. The method is thus advantageous when only minute quantities of the analyte are available, for instance in an early stage of the research. Major advantages of the method according to the invention are that automated set-up of the experiments is generally quicker for small volumes, the automated detection of crystals in an array of conditions is quicker as more samples can be tested simultaneously, less material is required thereby reducing wastage, more tests can be performed given the amount of material available, the chance that the conditions under which crystaUisation is achieved are identified significantly increases and the chances of identification of different polymorphic forms increases likewise. A preferred way of providing a set of compositions for determining crystallisation conditions for analytes is a method wherein said set of compositions is provided on a solid support medium comprising of a multitude of separate cells, each comprising one composition. In this manner an array-like test format is provided allowing for easy automation of dispensing compositions and or changing conditions per composition and of detection of phase change behaviour (typically crystallisation of the analyte). In any format the crystallisation may be best achieved by a further change to the conditions by allowing changes in any of the parameters through diffusion, evaporation, temperature change or other techniques or processes and combinations thereof. Such further changes in physical or chemical conditions can be applied in the present invention and very conveniently so in the array format. Further changes may also be used to fine tune the crystallisation conditions. The cells on the solid support are preferably further equipped with means for controlling the atmosphere in or directly above the cells. To this end the support medium is for instance fitted with sealing devices or sealing substances which seal off the entire support or seal off individual cells or groups of cells. To this end balls, plates, caps, inert liquids like paraffin oil, silicon oil, etc. can be provided. The analyte is brought in the cells of the solid support by techniques that allow for the precise and controlled delivery of minute amounts of matter. Suitable techniques are those that allow for the precise and controlled delivery of amounts of liquids or solids in the range of microliters or - grams, preferably nanoliters or - grams, more preferable picoUters or - grams. When the analyte is provided in any Uquid form, preferably dispensing techniques such as piezo-electric dispensing techniques, bubble-jet dispensing techniques, electro-spray dispensing techniques, as weU as other micro- and submicro-dispensing techniques can be used, preferably nano-dispensing techniques are used. By using these techniques for dispensing it is possible to provide each ceU with a predetermined amount of analyte. Hence, it is likewise possible to provide to each ceU a different amount of analyte. Also non-directional dispensing of a fluid onto the substrate, for instance by flood-filling by submerging the substrate into a fluid, pouring the fluid over the substrate, or other flood-filling techniques can be employed advantageously. When the analyte is provided by means of some carrier, for instance in the form of a solution or emulsion, it is a preferred option to remove at least partly solvents and/or other carrier fluids by aUowing or causing a degree of evaporation, drying, draining, lyophiUsation or other fluid removal technique from the ceUs. It is often desired to be able to influence the speed and duration of crystallisation processes, as weU as the size and size distribution and homogeneity and/or purity of resulting crystals. In order to do so the invention is particularly suitable. A fast formation of nuclei can be designed, foUowed by slow crystaUisation on those nuclei, if desired. Conditions on how to influence speed and growth and how to end crystaUisation can aU be determined. After that a production scale of crystals, for instance for pharmaceutical use (in pharmaceutical preparations) can be based on the conditions identified according to the invention. During crystal growth, gravity- induced convection that is caused by local concentration gradients that result from the accretion of molecules on the growing crystal, can adversely affect the crystaUine order of said crystal. In smaU volumes, this gravity-induced convection is far less severe, since next to the diffusion rate and the speed of crystal growth, said convection increases with the physical size of the container in which crystaUisation takes place. Therefore the present method will generaUy result in crystals that are better ordered than crystals grown in larger volumes, that are subjected to gravity. As the method reduces gravity induced convection during crystal growth, the crystaUine order of crystals produced with the method will approach that of high quaUty crystals grown in space, i.e. in microgravity conditions. The invention provides for the determination of crystaUisation conditions that aUow for the growth of different crystal forms of the analyte, thus enabling the identification of polymorphic forms from the analyte. This is valuable information, for instance in the case of a pharmaceutical whereby polymorphs of the pharmaceutical compound of interest can each have different physical properties or different properties in terms of biological activity. Official approval such as from the United States' Food and Drug Administration of a specific and weU-defined drug cannot be transferred to another polymorph of the same drug, although the chemical nature of the constituting molecules is identical. It is therefore very important that the various polymorphs of a drug are discovered and identified in order to gain an understanding of their biological properties. Furthermore, the early discovery of these drug polymorphs is also pharmaceuticaUy interesting as the different polymorphs may have a different biological activity, for instance through differences in solubility. The invention also provides a method for producing a composition comprising crystals of an analyte of a narrow size distribution, comprising selecting crystaUisation conditions for said analyte by a method according to the invention and scaUng up said conditions to a desired total volume, where crystals obtained by the method can be used as nucleation centres. The crystals obtained by such a method wiU be more homogeneous in size and composition than crystals obtained by methods avaflable until now. Thus the invention also encompasses these crystals. Such crystals can be used for pharmaceutical purposes or as seed crystals in further crystaUisation processes. In such an embodiment the invention provides a method for producing crystals of an analyte, comprising providing an over-saturated composition of said analyte and providing said over-saturated composition with seed crystals according to the invention. A preferred use of the crystals produced according to the invention is in the determination of structures of analytes. Thus the invention further provides a method for determining the structure of an analyte comprising subjecting crystals from said composition according to the invention to soUd state NMR techniques, neutron diffraction, electron diffraction and/or X-ray diffraction and determining its crystal structure. Preferably, the method is carried out in an array of separate ceUs, whereby each ceU contains a different composition. When a change in phase behaviour occurs, this is detected and can be correlated to the specific composition and conditions under which the screening is taking place. To provide for an increased reHability of the method, each combination may be provided in duplo or triplo on the same sohd support medium. Any crystal that does not have a cubic symmetry is known to change the polarisation of linearly polarised Ught, depending on its orientation with respect to the direction of polarisation of the through-falling Ught. This property of crystals and crystaUine biomaterial in particular, is at present being used to determine and inspect the quaUty of individual crystals. However, this property can also be used to determine the presence or absence of a crystal of an analyte that is non-cubic. By measuring the change in the polarisation of the Ught faUing through, as the direction of polarisation is changed, the presence of non-cubic crystaUine material can be determined. Preferably the change in phase behaviour of the analyte is caused by the formation of crystaUine material. This allows for the introduction of a separate step in the method for the detection of polymorphic behaviour. By first determining the presence of crystaUine material, the number of X-ray diffraction patterns that have to be recorded may be reduced. This aUows for a further increase in the efficiency of the method according to the invention. Changes in phase behaviour can be determined in various ways, but for the rapid screening of multiple samples under reproducible circumstances preferred techniques are based on the detection or measurement of, continuously or intermittently, optical and/or diffraction characteristics of the individual ceUs. The determination of the optical and/or diffraction characteristics of the individual ceUs can be done with a system comprising: - a Ught source the direction of polarisation of which can be varied - a holder for - a substrate comprising a multitude of ceUs - a system for detecting a change in the polarisation of the Ught coming from the polarisable Ught source. - a position sensitive detector. A change in the polarisation of the Ught generaUy corresponds to a change in phase behaviour. It is preferred that the change in phase behaviour is mainly due to a phase change of the analyte. A change in phase behaviour that is not caused by a phase change of the analyte may additionaUy provide useful and valuable information regarding the phase behaviour of the analyte itself. For example, if any salt crystaUises, whflst the substance of interest remains soluble, the substance of interest cannot be precipitated at its present concentration with said salt. Detecting phase changes can also be done by visual screening, for instance with the aid of microscopy techniques. The existence of polymorphs can then be determined by the previously described technique. The invention further provides as a specific embodiment a method for screening the crystaUisation behaviour of at least one analyte comprising the steps of: - providing a soUd support medium comprising of a multitude of separate cells, - combining the analyte in each separate ceU with one or more other components preferably such that the total composition of an individual ceU differs in at least one aspect from the composition of at least one other ceU, where the mixing of components and analytes is either simultaneously or in sequence, in any order; - optionaUy modifying the conditions that lead to changes in phase behaviour in individual compositions; - detecting changes in phase behaviour, more in particular crystaUisation, of the compositions in the separate ceUs. AdditionaUy to speed up the identification of ideal conditions, the different ceUs can be compared (automaticaUy) to each other. Of course the change in phase behaviour of the composition is preferably mainly caused by a phase change, more in particular by crystaUisation, of the analyte. To enhance crystaUisation of the analyte an inert nucleus or inert nuclei for crystaUisation may be provided. In one embodiment the invention thus provides a method wherein the surface of the support medium comprises at least one crystaUisation nucleus comprising an inert crystal, preferably those wherein the nucleation centres are in the form of smaU crystallites preferably of salts or complexes of the analyte. In another embodiment the (crystaUine) nature of the substrate itself may influence crystaUisation of the analyte. The crystaUisation initiation may further be influenced by a step in which nucleation is induced by agitation, vibration, micro-wave treatment, (ultra)sonic treatments or a combination thereof. Description of the figures Figure 1: The overaU layout of the microplate substrate with 96 containers. Figure 2: FUter holder. Figure 3: X-Y translation table on diffractometer. Figure 4: X-ray diffraction patterns of different polymorphs recorded in the microarray. Figure 5: X-ray powder diffraction patterns of polymorphs A, B and C of Figure 6: Pathways used to produce polymorphs B and C in bulk from polymorph A of F5O3NC18H2. Figure 7: MicroweU containing a polymorph of F5O3NC18H2. Examples A microbatch array designed to process organic and inorganic Uquids at elevated temperature and pressure was used. Materials were chosen to be as chemicaUy inert as possible, to aUow for a rapid heat transfer to and from the Uquid compartments. A microplate array with outer dimensions of 127.7 mm by 85.5 mm, containing 96 weUs was machined from brass, and was after machining gold plated. The volume of the microweUs is approximately 50 μL and the individual weUs are sealed with an O-ring made of a synthetic flexible polymer. For this purpose Viton® rings were used, but chemicaUy more inert rings like Kalrez® or Teflon® rings might be preferable. The weUs were closed by covering the O-rings by a 4 mm thick glass plate (length 117 mm, width 75 mm). To immobihse the glass plate on the microplate, a brass bracket is mounted with 16 smaU screws. The format of the microplate array is based on the standard size of a 96 weU microtitre plate. The brass microplate is bolted to a stainless steel adapter board that fits snugly into the heating element of a commercially avaflable 96-weU thermocycler. (Viton and Kalrez are registered trademarks of DuPont Dow Elastomers, Teflon is a registered tradename of DuPont Company.) The weUs or containers of the substrate are fiUed with any manual, semiautomatic or automatic pipetting or dispensing device. The analyte is introduced in solution, upon which the solvent can be evaporated. It may be important to thoroughly filter the solution of said analyte before introducing it in said containers. Subsequently other components or solvents can be introduced by pipetting. If some or aU of the analyte present in a container does not dissolve in its Uquid environment, the temperature may be raised, optionaUy after said container has been sealed, to a temperature that is sufficiently high to achieve total dissolution. A means of changing the conditions in the array of containers, resulting in crystaUisation of the analyte is optionaUy provided. By changing the temperature, by aUowing solvent to evaporate, or by a combination of these two processes, crystaUisation is induced in paraUel in one or more of the containers of said substrate. A means of analysis of the crystaUinity and identification of polymorphs in each of the soUd fractions in the array of containers is provided. OptionaUy, the soUd materials from each of the individual containers can be transferred simultaneously to a thin carrier membrane using one of a variety of different ways. For example, Whatman Polyfiltronics has developed a system for harvesting on a single filter, precipitated chemicals from a 96-weU plate by filtration, using a special suction system. A means of automated analysis and identification of physical properties of polymorphs on an array of containers is provided. The optional filter is mounted on an X-Z translation system, like the one manufactured by (Altechna Co. td.NUnius, Latvia) that is placed on an X-ray diffractometer, like an FRG-391 generator from Nonius (Delft, The Netherlands). (Transmission powder) X-ray diffraction patterns can be recorded on an area detector, like the MAR-345 image plate detector of MAR Research GmbH (Hamburg, Germany). X-ray diffraction patterns are recorded of each of the retentates that are held on the filter. After the exposure of one retentate has finished, the X-Z translation table moves the next retentate into the exposure position. The X-ray diffraction images are analysed and compared. Fluctuating backgrounds, due to e.g. non-uniformity of the filter, can be removed from the diffraction images before mutuaUy comparing the observed patterns. An example of the appUcation of the described technology is given below: Results on F5O3NC18H2 in microarray A single chemical compound (F5O3NC18H2, molecular weight: 393.36) was tested for crystaUising conditions and polymorphism, using a simple heating-cooUng cycle on a screen consisting of 16 different solvent compositions. The diffraction patterns of different polymorphs were identified automaticaUy using a cross- correlation method. The fuU screen consisted of 6 identical subsets. The identified polymorphs are indicated in table I. In some of the containers no polymorph could be identified. This may be due to the absence of crystaUinity and/or the very low amount of crystaUine material present. Out of 73 compounds classified, according to their X-ray diffraction, only two weUs contained material that was not a polymorph of the original material (polymorph A). The X-ray diffraction patterns of the three polymorphs are given in figure 4. In conclusion, it is possible to produce and detect polymorphs in smaU volumes. Relating the processing condition to the formation of the desired polymorph is possible. Further information was obtained from additional screens exploring the phase diagram in more detaU to find optimised processing conditions. Results on F5O3NC18H2 in bull- Two polymorphs B and C were produced from the original material, polymorph A, using a variety of pathways. The formation of polymorph B was found after dissolving polymorph A in water at elevated temperature 120° C and pressure. This seems to be an intermediate structure and several pathways could be used to obtain the polymorph C in bulk. The X-ray diffraction patterns of the three polymorphs are given in figure 5. In conclusion, both B and C can be produced in bulk using different pathways as shown in figure 6. The mass of polymorphs A and C was determined by ESI mass spectrometry and both masses were in agreement with the chemical composition as documented. It can be ruled out that polymorph B or C is a degradation product, since C can be produced from pure A via intermediate B. Table I: Identification of polymorphs on the micro-array the plate. In this table the non-itahc symbols A, B and C indicate the polymorph identification. Table II: Solvent composition of each microwell One gram of F5O3NC18H2 was dissolved in 4.5 gram ethylacetate p. a. and 20 μ L was added in two portions of 10 μL into each of the 96 weUs in the micro batch plate. The solvent was aUowed to evaporate by heating to 40° C in a conventional PCR machine with an open Ud for one hour. The foUowing 96 weU screen was set up with 4 solvent components: water (H2O), methanol (MeOH), 1-butanol (BuOH) and 2- propanol (i-PrOH). +Table III The composition of the 16 solvent screen was repeated six times on the 96 weU array.

Claims: Claims 1. A method for detecting polymorphism of at least one analyte, comprising the provision of a set of compositions, each said composition comprising at least one analyte, and inducing or aUowing each composition to adopt at least a first condition possibly influencing crystaUisation and detecting any crystaUisation in at least one composition. 2. A method according to claim 1, additionaUy comprising a step wherein detected crystaUisation in a composition is compared with detected crystallisation in the other compositions. 3. A method according to claim 1 or 2, wherein the analyte crystallises in different polymorphic forms. 4. A method for optimising the conditions of the transformation of one polymorphic form of an analyte into another polymorphic form by subjecting the one polymorphic form of the analyte to a method as defined in claim 1. 5. A method according to claims 1-3, wherein each member of said set of compositions differs in at least one condition from any other composition of said set. 6. A method according to claim 5, wherein said at least one condition comprises a physical condition. 7. A method according to claim 5, wherein said at least one condition comprises a chemical condition. 8. A method according to claim 5, wherein said set of compositions is provided on a soUd support medium comprising of a multitude of separate ceUs, each comprising one composition. 9. A method according to claim 5, further comprising changing at least one further condition after exposing the composition to said first condition. 10. A method according to claim 5, further comprising identifying conditions under which desired size and homogeneity of analytes are obtained. 11. A method according to any one of the foregoing claims wherein said analyte is a smaU organic molecule, an organometaUic compound, a catalyst, a salt of an organic molecule or pharmaceuticaUy active compound or a biomolecule. 12. A method to any of the previous claims, wherein the composition has a volume of less than 1000, preferably less than 100, more preferably less than 10 microUter. 13. A method for producing a composition comprising crystals of an analyte of a narrow size distribution, comprising selecting crystaUisation conditions for said analyte by a method according to any one of the foregoing claims and scaUng up said conditions to a desired total volume. 14. A composition comprising crystals of an analyte of a narrow size distribution obtainable by a method according to claim 10. 15. Use of a composition according to claim 10 as a source for crystaUisation nuclei in a crystaUisation process for said analyte. 16. A method for producing crystals of an analyte, comprising providing an oversaturated composition of said analyte and providing said oversaturated composition with a composition according to claim 14. 17. A method for determining the structure of an analyte comprising subjecting a composition or a crystal from said composition according to claim 10 to neutron diffraction, electron diffraction and/or X-ray diffraction and determining its crystal structure. 18. A method for screening the polymorphic behaviour of at least one analyte comprising the steps of: - providing a soUd support medium comprising of a multitude of separate ceUs, - providing two or more of the separate ceUs with the analyte and other components such that the total composition of an individual ceU differs in at least one aspect from the composition of at least one other ceU, - optionaUy modifying the conditions that lead to changes in crystaUisation behaviour in individual compositions; - detecting changes in polymorphic behaviour of the compositions in the separate ceUs by determining the crystal form of the analyte. 19. A method according to claim 18, additionaUy comprising a step wherein the composition of the ceU is further modified. 20. A method according to claim 18 or 19, additionaUy comprising a step wherein the crystal form is determined by neutron diffraction, electron diffraction or X-ray diffraction, preferably X-ray diffraction. 21. A method according to any one of claims 1-12 or 16-20, wherein the analyte is provided in the form of a crystalhne or aggregated state, solution, emulsion or a suspension. 22. A method according to claim 18-21, wherein the surface of the support medium comprises at least one crystaUisation nucleus comprising an inert crystal. 23. A method according to claims 1-12 or 18-22, wherein the ceUs have a volume or are filled to a total volume of at most at most 1000, preferably at most 100, more preferably at most 10 microUter. 24. A method according to claims 1-12 or 16-23, wherein the ceUs contain at most 100, preferably at most 10, more preferably at most 1 microgram of the analyte. 25. A method according to claims 18-24, wherein the change in crystaUisation behaviour of the analyte comprises the formation of crystaUine material of the analyte. 26. A method according to claim 25, wherein the formation of crystaUine material of the analyte comprises the formation of at least one polymorphic form of the crystaUine material. 27. A method according to claim 25 or 26, wherein the crystaUine material of the analyte comprises co-crystals of two or more analytes or of an analyte with a smaU molecule, like a salt or a solvate. 28. A method according to any one of claims 1-12 or 18-27, additionaUy comprising a step in which nucleation is induced by addition of nucleation centres, by agitation, vibration, micro-wave treatment, (ultra)sonic treatments or a combination thereof. 29. A method according to claim 28, wherein the nucleation centres are in the form of smaU crystaUites. 30. A method according to claim 29, wherein the smaU crystaUites are salts or complexes of the analyte. 31. A method according to any one of claims 1-12 or 18-27, wherein changes in crystaUisation behaviour are detected by measuring, continuously or intermittently, optical and/or diffraction characteristics of the individual ceUs. 32. A method according to any one of claims 1-12, or 18-30, wherein the analyte and/or components are added to the ceUs by piezo-electric dispensing techniques, bubble jet dispensing techniques, electrospray dispensing techniques, micro- and nano- dispensing techniques, or flood fiUing or combinations thereof. 33. Crystalline material obtainable by a method of any of the previous method claims.

Inventors: ABRAHAMS JAN PIETER, HOEDEMAEKER PHILIPPUS JACOBUS, KUIL MAXIM EMILE, MAXWELL IAN ERNEST, PLAISIER JASPER RIKKERT, ABRAHAMS, JAN, PIETER, HOEDEMAEKER, PHILIPPUS, JACOBUS, KUIL, MAXIM, EMILE, MAXWELL, IAN, ERNEST, PLAISIER, JASPER, RIKKERT
Applicants: ABRAHAMS JAN PIETER, AVANTIUM TECHNOLOGIES B V, HOEDEMAEKER PHILIPPUS JACOBUS, KUIL MAXIM EMILE, MAXWELL IAN ERNEST, PLAISIER JASPER RIKKERT, UNIV LEIDEN, ABRAHAMS, JAN, PIETER, AVANTIUM TECHNOLOGIES B.V., HOEDEMAEKER, PHILIPPUS, JACOBUS, KUIL, MAXIM, EMILE, MAXWELL, IAN, ERNEST, PLAISIER, JASPER, RIKKERT, UNIVERSITEIT LEIDEN
Application year: 2001
Main classification: G01N23
IPC codes: G01N23, G01N35, G01N37